Patents by Inventor Chandra Prakash Sharma

Chandra Prakash Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9137724
    Abstract: A method includes receiving a signal indicative that a first access point can transmit data over a first number of spatial streams, and a second access point can transmit data over a second number of spatial streams. The method includes receiving a probe request from a set of client devices. A first portion of the set of client devices is configured to transmit data over the first number of spatial streams and a second portion of the client devices is configured to transmit data over the second number of spatial streams. The method includes sending a signal to the first portion associated with authorizing the first portion to connect to the first access point and sending a signal to the second portion associated with authorizing the second portion to connect to the second access point.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 15, 2015
    Assignee: Juniper Networks, Inc.
    Inventor: Chandra Prakash Sharma
  • Publication number: 20150218262
    Abstract: A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibodysubstrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicant: TATA MEMORIAL CENTRE
    Inventors: Indraneel MITTRA, Rekha Mannemcherril RAMESAN, Chandra Prakash SHARMA, Gopichettipalayam Subbaratnam BHUVANESHWAR, Kavita Anirban PAL
  • Patent number: 9096655
    Abstract: A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: August 4, 2015
    Assignee: TATA MEMORIAL CENTRE
    Inventors: Indraneel Mittra, Rekha Mannemcherril Ramesan, Chandra Prakash Sharma, Gopichettipalayam Subbaratnam Bhuvaneshwar, Kavita Anirban Pal
  • Publication number: 20120301487
    Abstract: A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.
    Type: Application
    Filed: January 24, 2011
    Publication date: November 29, 2012
    Inventors: Indraneel Mittra, Rekha Mannemcherril Ramesan, Chandra Prakash Sharma, Gopichettipalayam Subbaratnam Vaneshwar, Kavita Anirban Pal
  • Publication number: 20090098205
    Abstract: The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also to incorporate pH sensitivity so that these particles shrink in the gastric acidic pH thereby protecting the incorporated insulin. These particles being also hydrophobic in nature and by virtue of their small size get absorbed through the intestinal cell wall and Peyer's patches. These nanoparticles are novel and unique in the sense that polymer content is only 0.03-0.06 g/g product and the polymer is hydrophilic in nature.
    Type: Application
    Filed: December 30, 2005
    Publication date: April 16, 2009
    Inventors: Chandra Prakash Sharma, Ramesan Rekha Mannemcherril